ASX:PAR - Paradigm Biopharmaceuticals Stock Price, News, & Analysis

-0.05 (-3.50 %)
(As of 06/17/2019 04:00 PM ET)
Today's Range
Now: A$1.38
50-Day Range
MA: A$1.48
52-Week Range
Now: A$1.38
Volume709,238 shs
Average VolumeN/A
Market Capitalization$265.25 million
P/E RatioN/A
Dividend YieldN/A
Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable and tablet forms for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company has a strategic partnership with the Pro Players' Elite Network to identify and assist sportspeople that have existing knee and joint pathologies that would benefit from treatment with injectable Pentosan Polysulfate Sodium. Paradigm Biopharmaceuticals Limited was incorporated in 2014 and is based in Melbourne, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Phone61 3 9629 5566



Sales & Book Value

Annual Sales$2.69 million
Cash FlowA$0.07 per share
Book ValueA$0.14 per share



Market Cap$265.25 million
Next Earnings DateN/A

Receive PAR News and Ratings via Email

Sign-up to receive the latest news and ratings for PAR and its competitors with MarketBeat's FREE daily newsletter.

Paradigm Biopharmaceuticals (ASX:PAR) Frequently Asked Questions

What is Paradigm Biopharmaceuticals' stock symbol?

Paradigm Biopharmaceuticals trades on the ASX under the ticker symbol "PAR."

Has Paradigm Biopharmaceuticals been receiving favorable news coverage?

Media stories about PAR stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Paradigm Biopharmaceuticals earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Paradigm Biopharmaceuticals.

Who are some of Paradigm Biopharmaceuticals' key competitors?

Who are Paradigm Biopharmaceuticals' key executives?

Paradigm Biopharmaceuticals' management team includes the folowing people:
  • Mr. Paul Rennie BSc, Grad Dip, MBM, MSTC, CEO, MD & Exec. Director (Age 60)
  • Mr. Kevin G. Hollingsworth, CFO & Company Sec. (Age 66)
  • Dr. Claire Kaufman, Chief Operations Officer
  • Dr. Ravi Krishnan, Chief Scientific Officer

What is Paradigm Biopharmaceuticals' stock price today?

One share of PAR stock can currently be purchased for approximately A$1.38.

How big of a company is Paradigm Biopharmaceuticals?

Paradigm Biopharmaceuticals has a market capitalization of $265.25 million and generates $2.69 million in revenue each year. View Additional Information About Paradigm Biopharmaceuticals.

What is Paradigm Biopharmaceuticals' official website?

The official website for Paradigm Biopharmaceuticals is

How can I contact Paradigm Biopharmaceuticals?

The company can be reached via phone at 61 3 9629 5566.

MarketBeat Community Rating for Paradigm Biopharmaceuticals (ASX PAR)

Community Ranking:  NaN out of 5 ()
Outperform Votes:  0 (Vote Outperform)
Underperform Votes:  0 (Vote Underperform)
Total Votes:  0
MarketBeat's community ratings are surveys of what our community members think about Paradigm Biopharmaceuticals and other stocks. Vote "Outperform" if you believe PAR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PAR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/17/2019 by Staff

Featured Article: Cost of Goods Sold (COGS)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel